VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 93 filers reported holding VERVE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 4.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $64,085,157 | -16.5% | 4,832,968 | +18.1% | 0.00% | 0.0% |
Q2 2023 | $76,710,282 | +37.1% | 4,091,215 | +5.5% | 0.00% | +100.0% |
Q1 2023 | $55,933,017 | -24.2% | 3,878,850 | +1.8% | 0.00% | -50.0% |
Q4 2022 | $73,762,664 | -41.3% | 3,812,024 | +4.2% | 0.00% | -50.0% |
Q3 2022 | $125,680,000 | +251.2% | 3,658,812 | +56.2% | 0.00% | +300.0% |
Q2 2022 | $35,789,000 | -32.4% | 2,342,193 | +1.0% | 0.00% | 0.0% |
Q1 2022 | $52,915,000 | +5.2% | 2,318,775 | +70.0% | 0.00% | 0.0% |
Q4 2021 | $50,300,000 | -16.6% | 1,364,221 | +6.4% | 0.00% | 0.0% |
Q3 2021 | $60,279,000 | +1438.9% | 1,282,542 | +1873.1% | 0.00% | – |
Q2 2021 | $3,917,000 | – | 65,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARCH Venture Management, LLC | 2,508,809 | $57,251,000 | 8.18% |
Alphabet Inc. | 10,974,011 | $250,427,000 | 8.12% |
M28 Capital Management LP | 178,500 | $4,073,000 | 3.74% |
Casdin Capital, LLC | 3,138,167 | $71,613,000 | 3.21% |
Ally Bridge Group (NY) LLC | 105,360 | $2,404,000 | 1.78% |
Redmile Group, LLC | 1,835,328 | $41,882,000 | 1.31% |
Cormorant Asset Management, LP | 700,710 | $15,990,000 | 1.23% |
Novo Holdings A/S | 750,000 | $17,115,000 | 0.90% |
Artal Group S.A. | 400,000 | $9,128,000 | 0.38% |
PFM Health Sciences, LP | 369,765 | $8,438,000 | 0.32% |